Navigation Links
ImpediMed and Metagenics Announce Agreement
Date:10/2/2008

BRISBANE, Australia and SAN CLEMENTE, Calif., Oct. 2 /PRNewswire/ -- ImpediMed Ltd, a pioneer in the medical applications of bioimpedance technology and Metagenics, Inc., a global leader in science-based nutraceutical products, medical foods, and therapeutic lifestyle change programs, today announced an agreement to distribute ImpediMed technology in the United States and Canada. Metagenics' Australian affiliate, Health World, Ltd, has been a long-standing customer of the Brisbane-based medical device manufacturer.

"We've seen the synergies of combining ImpediMed's products for assessing fat and fluid status with our own research-based health and wellness products and programs, which we market to healthcare professionals," said Mike Katke, VP of Medical Marketing for San Clemente, California-based Metagenics. "Their scientifically-grounded approach and the reliability and portability of their technology made offering ImpediMed to our customers a simple decision."

ImpediMed CEO Greg Brown said, "Metagenics has been an outstanding Australian partner using ImpediMed's body composition analysis devices for several years. This expanded relationship makes sense in light of our mutual focus on addressing wellness and healthier life styles."

About Metagenics, Inc.

Metagenics, Inc. is a life sciences company and leading developer and manufacturer of science-based nutraceuticals medical foods, and therapeutic lifestyle change programs marketed to healthcare practitioners worldwide. It is headquartered in San Clemente, Calif. with manufacturing and multiple research facilities located in Gig Harbor, Wash., including its MetaProteomics(R) Nutrigenomics Research Center and its Functional Medicine Research Center(SM) for human clinical research. Metagenics holds multiple proprietary formula patents and produces over 400 research-based products to optimize health. The company demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the NPA, NSF International, and TGA. For more information about Metagenics, please visit http://www.metagenics.com.

About ImpediMed Limited

ImpediMed Limited develops and globally markets medical device systems for use in non-invasive screening and monitoring of fluid status and body composition. ImpediMed's product range includes medical devices for body composition analysis and early detection and monitoring of secondary lymphedema in cancer survivors. ImpediMed's products are TGA and FDA cleared as well as CE marked for global distribution. For more information about ImpediMed, please visit http://www.impedimed.com

Contact:

Joseline Davison

Metagenics, Inc.

949-369-3406

josiedavison@metagenics.com

Jack Butler

ImpediMed

585-248-2554

jbutler@impedimed.com


'/>"/>
SOURCE ImpediMed Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
3. 2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced
4. BioSpace and BIOCOM Announce 2009 Biotech Beach(TM) Hotbed Campaign
5. Synthetech Announces New Director of Manufacturing
6. onTargetjobs and ClearedConnections Announce Online Recruitment Partnership
7. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
8. Biotel Announces Record Revenues and Earnings for Fiscal 2008
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Helix BioPharma Announces $11.4 Million Private Placement
11. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):